Fig. 4

MRTX1257 does not have any significant effect alone or in combination with RT in immunocompetent BALB/c mice bearing CT26 WT tumors. A BALB/c mice were subcutaneously inoculated with CT26 WT cells. Once the tumors reached an average volume of 90–100 mm³, mice received via oral administration 50 mg/kg of MRTX1257 or vehicle. The day after, mice received a single fraction of 6 Gy on the tumor mass. MRTX1257 at the dose of 50 mg/kg or vehicle were then administered at D1 and D3 after RT. The experiment was repeated three times. B Tumor growth (mean ± SEM). ***: p < 0.001 (two-way ANOVA). C Mean tumor volumes in each group 10 days after RT are represented. **: p < 0.01; ***: p < 0.001 (one-way ANOVA). D Individual growth profiles of CT26 KRAS G12C.^+/+ tumors are represented for each condition. The number of mice achieving durable response with no tumor being assessed at the end of the experiment is indicated below each panel. E Survival Kaplan–Meier curves were compared between each group using the log-rank test. ***: p < 0.001